High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome.


Journal

Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543

Informations de publication

Date de publication:
01 2020
Historique:
received: 01 07 2019
revised: 05 12 2019
accepted: 06 12 2019
pubmed: 27 12 2019
medline: 18 12 2020
entrez: 27 12 2019
Statut: ppublish

Résumé

Genetic partial lipodystrophies are rare heterogeneous disorders characterized by abnormalities of fat distribution and associated metabolic complications including a predisposition for atherosclerotic cardiovascular disease. We hypothesized that the milder forms of these diseases might be underdiagnosed and might result in early acute coronary syndrome (ACS) as the first sign of the pathology. We performed targeted sequencing on a panel of 8 genes involved in genetic lipodystrophy for 62 patients with premature ACS, and selected heterozygous missense variations with low frequency. To confirm those results, we analyzed a second independent group of 60 additional patients through Sanger sequencing, and compared to a control group of 120 healthy patients. In the first cohort, only PLIN1 exhibited variants in more than 1 patient. In PLIN1, 3 different variants were found in 6 patients. We then analyzed PLIN1 sequence in the second cohort with premature ACS and found 2 other patients. Altogether, 8 patients were carriers of 4 different mutations in PLIN1. The variant frequencies in the total cohort of 122 patients were compared to frequencies observed in a local control cohort and in 2 different public databases showing a significant difference between patient vs control group frequencies for two mutations out of 4 (c.245C > T p = 10 This is the first study that identifies a high frequency of potential pathogenic mutations in PLIN1 related to early onset ACS. These findings could contribute to the prevention and care of precocious ACS in families carrying those mutations.

Sections du résumé

BACKGROUND AND AIMS
Genetic partial lipodystrophies are rare heterogeneous disorders characterized by abnormalities of fat distribution and associated metabolic complications including a predisposition for atherosclerotic cardiovascular disease. We hypothesized that the milder forms of these diseases might be underdiagnosed and might result in early acute coronary syndrome (ACS) as the first sign of the pathology.
METHODS
We performed targeted sequencing on a panel of 8 genes involved in genetic lipodystrophy for 62 patients with premature ACS, and selected heterozygous missense variations with low frequency. To confirm those results, we analyzed a second independent group of 60 additional patients through Sanger sequencing, and compared to a control group of 120 healthy patients.
RESULTS
In the first cohort, only PLIN1 exhibited variants in more than 1 patient. In PLIN1, 3 different variants were found in 6 patients. We then analyzed PLIN1 sequence in the second cohort with premature ACS and found 2 other patients. Altogether, 8 patients were carriers of 4 different mutations in PLIN1. The variant frequencies in the total cohort of 122 patients were compared to frequencies observed in a local control cohort and in 2 different public databases showing a significant difference between patient vs control group frequencies for two mutations out of 4 (c.245C > T p = 10
DISCUSSION
This is the first study that identifies a high frequency of potential pathogenic mutations in PLIN1 related to early onset ACS. These findings could contribute to the prevention and care of precocious ACS in families carrying those mutations.

Identifiants

pubmed: 31877397
pii: S0021-9150(19)31608-9
doi: 10.1016/j.atherosclerosis.2019.12.002
pii:
doi:

Substances chimiques

Perilipin-1 0
DNA 9007-49-2

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-91

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Nathalie Bonello-Palot (N)

Aix Marseille Univ, INSERM, MMG, Marseille, France; APHM, CHU de la Timone, Laboratoire de Génétique Moléculaire, Marseille, France. Electronic address: nathalie.bonello@ap-hm.fr.

Marc Laine (M)

MARS Cardio, Mediterranean Association for Research and Studies in Cardiology, Intensive Care Unit, Hospital Nord, Marseille, France.

Thomas Cuisset (T)

Cardiology Department, CHU Timone, Marseille, France; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.

Thibault Ronchard (T)

MARS Cardio, Mediterranean Association for Research and Studies in Cardiology, Intensive Care Unit, Hospital Nord, Marseille, France.

Camille Desgrouas (C)

Aix Marseille Univ, INSERM, MMG, Marseille, France; Aix Marseille Univ, Laboratoire de Chimie Analytique, Faculté de Pharmacie, Marseille, France.

Françoise Merono (F)

Aix Marseille Univ, INSERM, MMG, Marseille, France.

Manal Ibrahim-Kosta (M)

Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.

Mathieu Cerino (M)

Aix Marseille Univ, INSERM, MMG, Marseille, France; APHM, CHU de la Timone, Laboratoire de Génétique Moléculaire, Marseille, France.

Arnaud Blanchard (A)

Aix Marseille Univ, INSERM, MMG, Marseille, France.

Patrice Bourgeois (P)

Aix Marseille Univ, INSERM, MMG, Marseille, France; APHM, CHU de la Timone, Laboratoire de Génétique Moléculaire, Marseille, France.

Nicolas Levy (N)

Aix Marseille Univ, INSERM, MMG, Marseille, France; APHM, CHU de la Timone, Laboratoire de Génétique Moléculaire, Marseille, France.

Anderson Loundou (A)

Aix Marseille Univ, Laboratoire de Chimie Analytique, Faculté de Pharmacie, Marseille, France.

Pierre-Emmanuel Morange (PE)

Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France; Service d'hématologie Biologique, Centre Hospitalo-universitaire Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France; CRB Assistance Publique - Hôpitaux de Marseille, HemoVasc (CRB AP-HM HemoVasc), Marseille, France.

Marie-Christine Alessi (MC)

Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France; Service d'hématologie Biologique, Centre Hospitalo-universitaire Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France.

Catherine Badens (C)

Aix Marseille Univ, INSERM, MMG, Marseille, France; APHM, CHU de la Timone, Laboratoire de Génétique Moléculaire, Marseille, France; Aix Marseille Univ, Laboratoire de Chimie Analytique, Faculté de Pharmacie, Marseille, France.

Laurent Bonello (L)

MARS Cardio, Mediterranean Association for Research and Studies in Cardiology, Intensive Care Unit, Hospital Nord, Marseille, France; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France. Electronic address: laurent.bonello@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH